• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

An Egg A Day Might Reduce Your Risk Of Heart Disease, Study Says
In this study however, they didn’t assess the risk of developing diabetes, which may be because diabetes is a newer disease in the Chinese population and there is not good documentation of who has it,” Richard said. Still, she noted, “this will be very important data for helping develop dietary prevention guidelines in China.” Cardiovascular disease, which takes the lives of 17.7 million people every year, is the leading cause of death and disability worldwide, according to the World Health Organization. Cardiovascular disease causes nearly a third — 31% — of all global deaths each year....
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Eggs Heart Disease Local TV Source Type: news

Following nature ' s rules, researchers develop new methods for treating degenerative neurological disease
Following nature's rules, researchers develop new methods for treating degenerative neurological disease The University of Arizona has licensed the new class of drugs designed to penetrate the blood-brain barrier to startup Teleport Pharmaceuticals. Paul Tumarkin Tuesday Tech Launch Arizonateleport-web-crop.jpg Robin Polt (right) coaches undergraduate student Hannah Kuo Feinberg as she works on a glycopeptide project in Polt ’s lab. Paul Tumarkin/Tech Launch ArizonaHealthScience and TechnologyCollege of Medicine - TucsonCollege of ScienceDeterminationExpertsExplorationTech Launch Arizona Media contact(s)Paul...
Source: The University of Arizona: Health - July 26, 2022 Category: Universities & Medical Training Authors: mittank Source Type: research

Associations between Greenness, Impervious Surface Area, and Nighttime Lights on Biomarkers of Vascular Aging in Chennai, India
Conclusion: Greenness, ISA, and NTL were associated with increased SBP, DBP, and cPP, and with reduced FMD, suggesting a possible additional EVA pathway for the relationship between urbanization and increased CVD prevalence in urban India. https://doi.org/10.1289/EHP541 Received: 20 May 2016 Revised: 03 January 2017 Accepted: 23 January 2017 Published: 02 August 2017 Address correspondence to K.J. Lane, Yale School of Forestry and Environmental Studies, 195 Prospect Street, New Haven, CT 06511 USA. Telephone: (781) 696-4537; Email: kevin.lane@yale.edu Supplemental Material is available online (https://doi.org/10.1289...
Source: EHP Research - August 2, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news